Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy | Zendy

Nienke van Rein | Zendy; Uffe HeideJørgensen | Zendy; Willem M. Lijfering | Zendy; Olaf M. Dekkers | Zendy; Henrik Toft Sørensen | Zendy; Suzanne C. Cannegieter | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy

Author(s) -

Nienke van Rein,

Uffe HeideJørgensen,

Willem M. Lijfering,

Olaf M. Dekkers,

Henrik Toft Sørensen,

Suzanne C. Cannegieter

Publication year - 2019

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.118.036248

Subject(s) - medicine , vitamin k antagonist , atrial fibrillation , interquartile range , hazard ratio , antithrombotic , warfarin , cohort , confidence interval

Patients with atrial fibrillation generally require anticoagulant therapy and, at times, therapy with additional platelet aggregation inhibitors. Data are scarce on bleeding rates in high-risk groups receiving combination therapy, such as the elderly or patients with a high CHA 2 DS 2 -VASc score.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research